Expertise in
2
conditions

Dr. Kishor M. Bhende

Pediatric Hematology Oncology
4102 24th Street, Suite 205, 
Anchorage, TX 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
2
conditions
4102 24th Street, Suite 205, 
Anchorage, TX 

Overview

Kishor Bhende is a Pediatric Hematologist Oncology provider practicing medicine in Anchorage, Texas.

Dr. Bhende is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Rhabdoid Tumor, Ewing Sarcoma, Neuroblastoma, Reticulohistiocytoma, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 33 clinical trials. Dr. Bhende is currently accepting new patients.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatrics in TX

Languages Spoken

English
Arabic
Cantonese
Hindi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
El Paso Health
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
FirstCare
  • HMO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 9 Less Insurance Carriers -

Locations

4102 24th Street, Suite 205, Anchorage, TX 79410

Additional Areas of Focus

Dr. Bhende has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

33 Clinical Trials

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
View 9 Less Clinical Trials

2 Total Publications

The influence of individual and neighborhood-level characteristics on rural-urban disparities in cardiovascular disease mortality among U.S. women diagnosed with breast and gynecologic cancers.
The influence of individual and neighborhood-level characteristics on rural-urban disparities in cardiovascular disease mortality among U.S. women diagnosed with breast and gynecologic cancers.
Journal: Gynecologic oncology
Published: October 12, 2020
Similar Doctors
Expertise in
2
conditions
Dr. Erin K. Barr
Pediatric Hematology Oncology
Expertise in
2
conditions
Dr. Erin K. Barr
Pediatric Hematology Oncology
Referral may be required
Before you request
4102 24th Street, Suite 205, 
Lubbock, TX 
 (0.7 miles away)
806-725-4840
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erin Barr is a Pediatric Hematologist Oncology provider practicing medicine in Lubbock, Texas. Dr. Barr is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration. Dr. Barr is currently accepting new patients.

Expertise in
0
conditions
Dr. Mohamad M. Al-Rahawan
Pediatric Hematology Oncology
Expertise in
0
conditions
Dr. Mohamad M. Al-Rahawan
Pediatric Hematology Oncology
Referral may be required
Before you request
4102 24th Street, Suite 205, 
Lubbock, TX 
 (0.7 miles away)
806-725-4840
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohamad Al-Rahawan is a Pediatric Hematologist Oncology provider practicing medicine in Lubbock, Texas. His clinical expertise encompasses Pineoblastoma, Acute Lymphoblastic Leukemia (ALL), Hereditary Spherocytosis, and Immune Thrombocytopenic Purpura (ITP). Dr. Al-Rahawan is currently accepting new patients.

Expertise in
0
conditions
Dr. Chibuzo C. O'suoji
Pediatric Hematology Oncology
Expertise in
0
conditions
Dr. Chibuzo C. O'suoji
Pediatric Hematology Oncology
Referral may be required
Before you request
4102 24th Street, Suite 205, 
Lubbock, TX 
 (0.7 miles away)
806-725-4840
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chibuzo O'suoji is a Pediatric Hematologist Oncology provider practicing medicine in Lubbock, Texas. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Immune Thrombocytopenic Purpura (ITP), and Neurofibromatosis Type 1 (NF1). Dr. O'suoji is currently accepting new patients.

Frequently Asked Questions about Dr. Kishor M. Bhende

How do I make an appointment with Dr. Kishor M. Bhende?

You can book an appointment with Dr. Kishor M. Bhende by calling their office at 806-725-4840. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kishor M. Bhende a top-rated expert for Rhabdoid Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kishor M. Bhende is classified as an Advanced expert for Rhabdoid Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kishor M. Bhende specialize in?

While Dr. Kishor M. Bhende is a Pediatric Hematology Oncology, they have specific expertise in Rhabdoid Tumor, Ewing Sarcoma, and Neuroblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Hematology Oncology.

Does Dr. Kishor M. Bhende participate in research or clinical trials?

Yes. Dr. Kishor M. Bhende has published 2 articles and abstracts on conditions like Rhabdoid Tumor. You can view a list of Dr. Kishor M. Bhende's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kishor M. Bhende accept my insurance?

Dr. Kishor M. Bhende accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 806-725-4840 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bhende's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile